Arix Bioscience PLC represents a commitment to innovation, scientific excellence, and long-term value creation. As a leading biotech investment company, Arix focuses on partnering with exceptional life science entrepreneurs and businesses to advance breakthrough therapies and technologies. Arix is dedicated to supporting companies with exciting potential, fostering collaborations, and driving growth within the biotech industry. By leveraging its vast network, expertise, and investment capital, Arix Bioscience PLC seeks to maximize its impact in improving global health while delivering strong returns for its shareholders. Arix's corporate philosophy revolves around identifying and nurturing bold ideas that have the potential to transform patient outcomes and shape the future of medicine.

Arix Bioscience PLC is primarily present in multiple countries and regions across the globe. The company has a strong global footprint, with its main presence in the United Kingdom, Europe, and North America. Arix Bioscience PLC actively engages in investments and partnerships within these regions to fuel its growth and innovation in the biotech sector. As an internationally recognized biotech company, Arix Bioscience PLC has established a notable presence in key life sciences hubs, including London, New York, and various European cities, enabling it to capitalize on potential investment opportunities and valuable cross-border collaborations.

Arix Bioscience PLC has achieved several significant milestones. The company successfully raised £100 million during its IPO in 2017 to support its mission. Since then, it has made notable investments in innovative life science companies, fostering growth and advancing breakthrough technologies in the healthcare sector. Arix Bioscience PLC has established strategic partnerships with renowned organizations, collaborating on research and development initiatives. With a dedicated team of experienced professionals, the company continues to drive progress in the biotechnology industry, aiming to improve patient outcomes and revolutionize healthcare. Arix Bioscience PLC's commitment to innovation and strategic investments positions it as a leading player in the life sciences field.

Arix Bioscience PLC is a renowned biotechnology investment company with a rich history and noteworthy background. Founded in 2016, Arix Bioscience PLC focuses on identifying and supporting medical innovations that have the potential to transform patients' lives. The company collaborates with leading academic institutions, research organizations, and biotech companies to provide capital and expertise in the development of breakthrough therapies. Arix Bioscience PLC emphasizes long-term value creation by investing in promising life science ventures across various therapeutic areas. With a strong track record, Arix Bioscience PLC continues to foster advancements in the biotech industry, consistently driving innovation and delivering potential returns to its shareholders.

The main competitors of Arix Bioscience PLC in the market include other biotechnology companies such as Vertex Pharmaceuticals, Moderna Therapeutics, Gilead Sciences, and Amgen.

Arix Bioscience PLC primarily operates in the biotechnology and healthcare industries.

The business model of Arix Bioscience PLC revolves around identifying and investing in innovative life science companies. Arix Bioscience PLC aims to provide long-term value to its shareholders by partnering with and supporting these companies to develop and commercialize breakthrough therapies and technologies. By leveraging its experienced team and global network, Arix Bioscience PLC seeks to unlock the full potential of these companies, driving growth and delivering impactful healthcare solutions. Through strategic investments and collaborations, Arix Bioscience PLC actively contributes to the advancement of the life sciences sector, ensuring a brighter future for patients and investors alike.

Det Arix Bioscience P/E-forhold er 0.

Arix Bioscience KUV er 0.

AlleAktien Kvalitetsscore for Arix Bioscience er 1/10.

Omsætningen kan i øjeblikket ikke beregnes for Arix Bioscience.

Overskuddet kan i øjeblikket ikke beregnes for Arix Bioscience.

Arix Bioscience PLC is an investment company that invests in biotechnology companies and supports them in maximizing their potential. The company's business model is based on analyzing emerging biotech companies with groundbreaking innovations and supporting their research to bring innovative products and therapies to market. Arix focuses on three main areas: science, corporate development, and fundraising. In the field of science, Arix works with brilliant scientists and researchers to develop groundbreaking innovations and new technologies and implement them into practice. The company identifies promising technologies and therapeutic approaches that have the potential to address unmet medical needs in various areas, including oncology, immunology, neurology, and metabolic diseases. Arix also offers support in corporate development to maximize the success of startups and emerging biotech companies. The company can draw on a wide range of experience and expertise to advise its portfolio companies and help them optimize their business strategies, expand their resources, and achieve their clinical and regulatory milestones. Another important area of Arix is fundraising. The company helps its portfolio companies secure funding to support the research and development of innovative products and therapies. Arix itself also invests directly in its portfolio companies to maximize their growth potential. The company leverages its extensive contacts in the biotechnology industry to develop and implement strategies for portfolio companies to accelerate growth and maximize potential for investors. Products and services offered by Arix Bioscience PLC include groundbreaking therapeutics and drugs for treating numerous diseases that have unmet needs in the medical industry. Arix invests in companies that achieve significant advances in the development of therapies and diagnostic methods focused on fighting diseases such as cancer, Alzheimer's, Parkinson's, and others. Additionally, Arix also invests in companies focused on the development of drugs and therapies for rare and genetic diseases. In summary, Arix Bioscience PLC is an innovative investment company with a strong focus on the biotechnology industry. The company has already built an impressive portfolio consisting of promising emerging biotech companies that are developing groundbreaking innovations and achieving significant progress in addressing unmet medical needs. Arix works with its portfolio companies to maximize their growth and success opportunities.

Arix Bioscience udbetaler et udbytte på 0 GBP fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Arix Bioscience, eller selskabet udbetaler ikke udbytte.

ISIN'en for Arix Bioscience er GB00BD045071.

WKN for Arix Bioscience er A2DL9L.

Tickeren for Arix Bioscience er ARIX.L.

I løbet af de sidste 12 måneder betalte Arix Bioscience en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Arix Bioscience sandsynligvis betale en dividende på 0 GBP.

Udbytteafkastet for Arix Bioscience er i øjeblikket .

Arix Bioscience betaler kvartalsvis udbytte. Dette uddeles i månederne .

Arix Bioscience betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 GBP. Dette svarer til et dividendeafkast på 0 %.

Arix Bioscience bliver tildelt sektoren 'Finans'.

For at modtage det seneste udbytte på Arix Bioscience fra den 8.9.2024 på 0 GBP, skulle du have haft aktien i din portefølje før ex-datoen den 8.9.2024.

Udbetalingen af det sidste udbytte blev foretaget den 8.9.2024.

I løbet af 2023 udbetalte Arix Bioscience 0 GBP i form af dividender.

Udbytterne fra Arix Bioscience udbetales i GBP.